X hits on this document

40 views

0 shares

0 downloads

0 comments

13 / 13

5. REFERENCES

Brownlee, Shannon. (4 April 2004). Doctors without borders: Why you can’t trust medical journals anymore

.WashingtonMonthly.http://www.washingtonmonthly.com/features/2004/0404.bro wnlee.html.Carroll, Bernard J., and Rubin, Robert T. (2003). Correspondence: Editorial polices on financial disclosure.Nature Neuroscience 6.10: 999.

Drugs and Pharmaceuticals: International Pharmaceutical Industry-A Snapshot, Jan 2004, ICRA

Pharmaceuticals: The Indian Pharmaceutical Industry, Feb 2005, ICRA.

. “International Marketing Strategies in India” by Prathap and Micheal, Vikalpa (IIMA),Oct-Dec 2005.

.Agarwal, S., Desai, S., Holcomb, M. and Oberoi, A. 2001, ‘Unlocking the value of Big Pharma’,The McKinsey Quarterly, No. 2.pp. 65-73.

.AstraZeneca 2001, ‘AstraZeneca Approach to E-Business’, presentation to analysts, New York.

.Blumberg, D. and Perrone, F. 2001, How Much are Marketing and Sales Capabilities ReallyWorth? A European Study on How the Capabilities Drive Performance, the European Study,

.Pharmaceutical Research and Manufacturers of America (PHARMA) 2001, PharmaceuticalIndustry Profile 2001, Washington.

AZOULAY,Pierre (2001), “Do Pharmaceutical Sales Respond to Scientific

.

ORG MARG Retail Audit,2002. ORG MARG: New Delhi.

Venugopal, P.V.1999. Industrial property and pharmaceutical opportunities and challenges for developing countries.

Smarta, Raja B. (1994). Strategic Pharmaceutical Marketing.

  • .Tufts Centre for the Study of Drug Development 2001, ‘Tufts Center for the Study of Drug Development Pegs Cost of a New Prescription Medicine at $802 Million’, Press Release, 30November.

industry:

Evidence ? Evidence from Anti-ulcer Drugs Department, Columbia University.

” working paper, Management

Document info
Document views40
Page views40
Page last viewedFri Dec 09 17:24:53 UTC 2016
Pages13
Paragraphs196
Words3752

Comments